EQ

Equillium, Inc. is a clinical-stage biotechnology company based in La Jolla, California, specializing in the development of innovative therapeutics for severe autoimmune and inflammatory disorders where treatment options are limited. By leveraging its proprietary platform, Equillium targets specific immuno-inflammatory pathways, reinforcing its position as a leader in addressing complex diseases. The company is advancing a promising pipeline of clinical candidates designed to meet significant unmet medical needs, thus aiming to improve patient outcomes and create value within the biopharmaceutical industry.